We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · February 20, 2021

Nanoparticle Albumin-Bound Paclitaxel With Cetuximab and Carboplatin as First-Line Therapy for Recurrent or Metastatic Head and Neck Cancer

Oral Oncology

 

Additional Info

Disclosure statements are available on the authors' profiles:

Oral Oncology
Nanoparticle Albumin-Bound Paclitaxel With Cetuximab and Carboplatin as First-Line Therapy for Recurrent or Metastatic Head and Neck Cancer: A Single-Arm, Multicenter, Phase 2 Trial
Oral Oncol 2021 Apr 01;115(xx)105173, Douglas Adkins, Jessica Ley, Omar Atiq, et al

Further Reading